BACKGROUND: Given the significant activity and tolerability of gemcitabine in patients with relapsed Hodgkin's lymphoma (HL), the critical role that nuclear factor kappa B (NF-kappaB) appears to play in the pathogenesis of this tumor, the ability of bortezomib to inhibit NF-kappaB activity, and laboratory studies suggesting synergistic antitumor effects of gemcitabine and bortezomib, we hypothesized that this combination would be efficacious in patients with relapsed or refractory HL. PATIENTS AND METHODS: A total of 18 patients participated. Patients received 3-week cycles of bortezomib 1 mg/m(2) on days 1, 4, 8, and 11 plus gemcitabine 800 mg/m(2) on days 1 and 8. RESULTS: The overall response rate for all patients was 22% (95% confidence interval 3% to 42%). Three patients developed grade III transaminase elevation: one was removed from the study and two had doses of gemcitabine held. Almost all patients exhibited inhibition of proteasome activity with treatment. CONCLUSIONS: The combination of gemcitabine and bortezomib is a less active and more toxic regimen in relapsed HL than other currently available treatments. It poses a risk of severe liver toxicity and should be pursued with caution in other types of cancer.
BACKGROUND: Given the significant activity and tolerability of gemcitabine in patients with relapsed Hodgkin's lymphoma (HL), the critical role that nuclear factor kappa B (NF-kappaB) appears to play in the pathogenesis of this tumor, the ability of bortezomib to inhibit NF-kappaB activity, and laboratory studies suggesting synergistic antitumor effects of gemcitabine and bortezomib, we hypothesized that this combination would be efficacious in patients with relapsed or refractory HL. PATIENTS AND METHODS: A total of 18 patients participated. Patients received 3-week cycles of bortezomib 1 mg/m(2) on days 1, 4, 8, and 11 plus gemcitabine 800 mg/m(2) on days 1 and 8. RESULTS: The overall response rate for all patients was 22% (95% confidence interval 3% to 42%). Three patients developed grade III transaminase elevation: one was removed from the study and two had doses of gemcitabine held. Almost all patients exhibited inhibition of proteasome activity with treatment. CONCLUSIONS: The combination of gemcitabine and bortezomib is a less active and more toxic regimen in relapsed HL than other currently available treatments. It poses a risk of severe liver toxicity and should be pursued with caution in other types of cancer.
Authors: B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: P L Zinzani; M Bendandi; V Stefoni; P Albertini; F Gherlinzoni; M Tani; P P Piccaluga; S Tura Journal: Haematologica Date: 2000-09 Impact factor: 9.941
Authors: F Emmerich; M Meiser; M Hummel; G Demel; H D Foss; F Jundt; S Mathas; D Krappmann; C Scheidereit; H Stein; B Dörken Journal: Blood Date: 1999-11-01 Impact factor: 22.113
Authors: David P Ryan; Leonard J Appleman; Thomas Lynch; Jeffrey G Supko; Panagiotis Fidias; Jeffrey W Clark; Mayer Fishman; Andrew X Zhu; Peter C Enzinger; Oscar Kashala; James Cusack; Joseph P Eder Journal: Cancer Date: 2006-11-15 Impact factor: 6.860
Authors: A Santoro; H Bredenfeld; L Devizzi; H Tesch; V Bonfante; S Viviani; F Fiedler; H S Parra; C Benoehr; M Pacini; G Bonadonna; V Diehl Journal: J Clin Oncol Date: 2000-07 Impact factor: 44.544
Authors: Sven Trelle; Orhan Sezer; Ralph Naumann; Mathias Rummel; Ulrich Keller; Andreas Engert; Peter Borchmann Journal: Haematologica Date: 2007-04 Impact factor: 9.941
Authors: Kristie A Blum; Jeffrey L Johnson; Donna Niedzwiecki; George P Canellos; Bruce D Cheson; Nancy L Bartlett Journal: Leuk Lymphoma Date: 2007-07
Authors: Sarah F Keller; Jennifer L Kelly; Elizabeth Sensenig; Jennifer Andreozzi; Jamie Oliva; Lynn Rich; Louis Constine; Michael Becker; Gordon Phillips; Jane Liesveld; Richard I Fisher; Steven H Bernstein; Jonathan W Friedberg Journal: Biol Blood Marrow Transplant Date: 2011-08-24 Impact factor: 5.742
Authors: Patrick B Johnston; David J Inwards; Joseph P Colgan; Betsy R Laplant; Brian F Kabat; Thomas M Habermann; Ivana N Micallef; Luis F Porrata; Stephen M Ansell; Craig B Reeder; Vivek Roy; Thomas E Witzig Journal: Am J Hematol Date: 2010-05 Impact factor: 10.047
Authors: Mei Lan Tan; Jer Ping Ooi; Nawfal Ismail; Ahmed Ismail Hassan Moad; Tengku Sifzizul Tengku Muhammad Journal: Pharm Res Date: 2009-04-30 Impact factor: 4.200